Investors
News
Contact

About us
Inhalers
- ICOres
- ICOcap
- ICOpre
- ICOone
- ICOone Nasal
- Patents
Development capabilities
Pipeline
Partner with us
Investors
Search
Menu Menu

Interim Report for Q1 2022 available in English

May 4, 2022/in News /by Eva Norell

The abbreviated Interim Report for January to March 2022 is now avaialble in English.

Read it here

Share this entry

Share on Twitter
Share on LinkedIn
Share by Mail

https://www.iconovo.se/wp-content/uploads/2022/05/Linkedin-Press-Releases-1.jpg 1000 1910 Eva Norell https://www.iconovo.se/wp-content/uploads/2026/01/Breathtaking-innovation_Iconovo-300x92-2026.png Eva Norell2022-05-04 10:27:232022-05-11 22:39:47Interim Report for Q1 2022 available in English

Possessing a unique combination

of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.

ICONOVO AB

VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B

POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden

CONTACT

Phone: +46 46 275 67 77

Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se

Interim CEO
Anders Månsson
Mail: anders.mansson@iconovo.se

Press releases

Follow us on Linkedin

Iconovo and Galenica enters a strategic collaboration for the development of...

Kapitalmarknadsdag med Iconovo 1 juni 2022 / Capital Markets Day June 1st in...